SLC5A2 and COVID-19: The empagliflozin is an inhibitor of the sodium-glucose cotransporter 2 (SGLT2) used in the treatment of type 2 diabetes, whose potential utility in patients with COVID-19 has been suggested [28] but not demonstrated yet.